Daewoo Pharmaceutical Co., Ltd.
Form 483 issued January 15, 2025 · Busan, South Korea
- Observations
- 13
- Pages
- 18
- FEI number
- 1000448124
In short: On January 15, 2025, FDA issued a Form 483 with 13 observations to Daewoo Pharmaceutical Co., Ltd. in Busan, Busan (FEI 1000448124). Most observations concern production and facilities & equipment; the most-cited regulation is 21 CFR 211.113 (control of microbiological contamination).
At a glance
Observations span 4 systems, led by production.
Most cited: 21 CFR 211.113 (3×) · 211.42 (2×)
What FDA observed
Preview: the opening words of each observationDashed: section inferred by FDA Intel and checked against the regulation text
- 01
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include…
- 02
Procedures designed to prevent microbiological contamination of drug products purporting to be…
- 03
Aseptic processing areas are deficient regarding the system…
- 04
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic…
This inspection in context
Questions about this 483
What did FDA find at Daewoo Pharmaceutical Co., Ltd.?
FDA listed 13 observations on this Form 483, mostly about production, facilities & equipment and quality system. The most-cited regulation is 21 CFR 211.113 (control of microbiological contamination). The opening words of each observation are shown on this page.
When was Daewoo Pharmaceutical Co., Ltd. inspected by FDA?
This Form 483 is dated January 15, 2025.
How do I get the full Form 483 for Daewoo Pharmaceutical Co., Ltd.?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.